Evaluation of the provision of crossmatch compatible platelets for haematology patients who have acquired non-immune refractoriness

Platelet demand is unpredictable and will relate to case mix, programmes of treatment requiring intensive platelet support and health service activity. Other relevant factors include the impact of clinical practice guidelines which have the potential when implemented to reduce the increase in demand or supress the clinical application of platelet component transfusion (Morris, K. 2018). Although platelet transfusions are vital to the ongoing management of patients with haematological malignancies, many patients become refractory to platelet transfusion. Refractoriness is defined as having a poor response (immediate or 24-hour increment post platelet transfusion of